Champions Oncology Records Strong Operational Performance in Q3 2026
Champions Oncology, a leading translational oncology services company, has announced strong operational performance in its third quarter fiscal year 2026 earnings call. The company delivered another quarter of record services revenue, underscoring the strength of its core translational oncology services platform and the resilience of customer relationships.
According to Rob Brainin, CEO of Champions Oncology, the company's PDX bank remains a true differentiator in the market, allowing it to continue seeing bookings convert into revenue as customer budgets stabilize. The operations team successfully delivered this growth without material additions to headcount, reflecting the operating leverage in the company's model and its ability to expand margins as it scales.
Quarterly revenue can fluctuate depending on the timing of study progression and completion, but the underlying demand for Champions Oncology's services remains healthy. The company focuses on expanding the pipeline of future work through increased commercial engagement, with strong conversion of previously booked work benefiting revenue in the period.
While year-over-year revenue showed a slight decline due to a large data deal closed in the third quarter last year, the company's services revenue came close to fully offsetting that comparison. Stepping back from the quarter-to-quarter noise, Champions Oncology remains on track for full-year revenue growth and positive adjusted EBITDA.
The company continues to invest in its data business and Corellia, its wholly owned target discovery subsidiary, without diluting Champions shares. This balance of growth and investment, coupled with disciplined focus on the bottom line, is central to how the company is managing itself.
While EBITDA remains somewhat suppressed in the near term as a result of investing in these growth drivers, the payoff from those investments is expected to begin showing up in fiscal 2027 with more meaningful acceleration in fiscal 2028. In terms of its data business, Champions Oncology has begun to see tangible signs of momentum, including the closure of a six-figure data deal that will be recognized in Q4.
The company also continues to progress its large data deal from Q3 of fiscal 2025, with incremental revenue expected in the fourth quarter. Customer engagement remains strong, and strategic discussions are underway with partners who recognize the value of combining deep biological annotation with clinically relevant tumor models.
These developments are encouraging, as they reflect the potential for substantial growth in Champions Oncology's data business. With a continued focus on expanding its pipeline of future work through increased commercial engagement, the company is well-positioned to drive growth and deliver value to its customers and shareholders alike.
